Results of DCCR Extension Study Support FDA Application, Soleno Says

Results of DCCR Extension Study Support FDA Application, Soleno Says

305616

Results of DCCR Extension Study Support FDA Application, Soleno Says

One year of treatment with Soleno Therapeutics’ investigational oral therapy diazoxide choline controlled release, known as DCCR, significantly reduced excessive appetite and disease-related behaviors in Prader-Willi syndrome (PWS) patients, according to top-line data from an extension study of the DESTINY PWS Phase 3 trial. These trajectories were significantly different from what happens in the natural course of the disease — which is being assessed in the ongoing observational PATH for PWS trial, or PfPWS (NCT03718416). According…

You must be logged in to read/download the full post.